
|Videos|December 18, 2020
Safety and efficacy of KPI-121 0.25% for DED treatment
Author(s)David Hutton
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Advertisement
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Johnson & Johnson’s TECNIS PureSee EDOF IOL cleared for US market
2
Eichenbaum Acorns: Collaborative retina care with Jeffry D. Gerson, OD, FAAO
3
Ophthalmic drug shortages more frequent, longer lasting than average
4
FDA clears phase I/II trial of SVT-001 cell therapy for familial drusen–associated vision loss
5

































